Product Description
RVT-802 is a one-time tissue-based regenerative therapy for the treatment of pediatric patients with congenital athymia. (Sourced from: https://enzyvant.com/enzyvant-resubmits-biologics-licensing-application-bla-to-fda-for-rvt-802-for-pediatric-congenital-athymia/)
Mechanisms of Action: Cell Therapy
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enzyvant Therapeutics
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Genetic Diseases, Inborn
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|